Methimazole (Neomercazole) in Pregnancy
First Trimester: Avoid Methimazole
Propylthiouracil (PTU) is the mandatory first-line agent during the first trimester of pregnancy, and methimazole (Neomercazole) should be avoided entirely during this period due to its association with specific congenital malformations. 1, 2, 3
Teratogenic Risk Profile
The FDA warns that methimazole crosses the placental membranes and causes rare but specific congenital defects when used in the first trimester, including aplasia cutis (scalp defects), choanal atresia, esophageal atresia with or without tracheoesophageal fistula, facial dysmorphism, omphalocele, and abnormalities of the omphalomesenteric duct. 3
A 2023 meta-analysis confirmed that pregnant women treated with methimazole had a significantly higher risk of congenital anomalies compared to those treated with PTU (OR 0.80,95% CI 0.69-0.92, P = 0.002). 4
The absolute risk of these malformations remains very small, but the pattern is distinctive and causally linked to first-trimester methimazole exposure. 5, 6
Second and Third Trimesters: Switch to Methimazole
After completing the first trimester (≥14 weeks gestation), switch from PTU to methimazole for the remainder of pregnancy to minimize maternal hepatotoxicity while avoiding the critical window for methimazole-induced birth defects. 1, 2
Rationale for Switching
PTU carries a risk of severe, potentially fatal hepatotoxicity that has prompted an FDA black box warning; this risk is substantially lower with methimazole. 3, 5, 6
PTU-induced hepatotoxicity occurs in approximately 0.1% of exposed adults and can progress to acute liver failure requiring transplantation. 6
The teratogenic window for methimazole-associated malformations is confined to organogenesis in the first trimester; exposure after 14 weeks does not carry the same structural defect risk. 1, 5
Failing to switch from PTU to methimazole after the first trimester unnecessarily exposes the mother to ongoing hepatotoxicity risk. 1
Dosing and Monitoring Guidelines
Treatment Target
Maintain free T4 or free thyroxine index (FTI) in the high-normal range using the lowest effective dose of thioamide. 1, 2
The goal is mild maternal hyperthyroidism rather than full euthyroidism to prevent fetal thyroid suppression, as methimazole readily crosses the placenta. 1, 3
Monitoring Schedule
Check free T4 or FTI every 2–4 weeks throughout the second and third trimesters to guide dose adjustments. 1, 2
Once biochemically stable, check TSH every trimester to confirm ongoing control. 1, 2
Dosing Strategy
Use the minimum dose of methimazole required to achieve the high-normal free T4 target, thereby limiting fetal drug exposure while maintaining maternal disease control. 1, 3
Dose methimazole based on actual body weight using the same mg/m² or mg/kg dosing as in non-pregnant patients. 7
Safety Monitoring
Agranulocytosis
Instruct patients to immediately report sore throat or fever, which may signal agranulocytosis—a potentially life-threatening complication. 1, 2, 3
Obtain a complete blood count immediately if these symptoms develop and discontinue methimazole if agranulocytosis is confirmed. 1, 3
Hepatotoxicity
Although methimazole carries lower hepatotoxic risk than PTU, monitor for symptoms of liver dysfunction (anorexia, pruritus, right upper quadrant pain). 3
Discontinue methimazole promptly if hepatic transaminases exceed 3 times the upper limit of normal. 3
Vasculitis
Rare cases of ANCA-positive vasculitis (including leukocytoclastic cutaneous vasculitis, glomerulonephritis, pulmonary hemorrhage, and CNS vasculitis) have been reported with methimazole. 3
Discontinue therapy and initiate appropriate intervention if vasculitis is suspected. 3
Adjunctive Symptom Management
Use a beta-blocker (e.g., propranolol) temporarily to control tremor, palpitations, and tachycardia until methimazole lowers thyroid hormone levels. 1, 2
Discontinue the beta-blocker once biochemical control is achieved, as it does not address the underlying thyroid hormone excess. 1
Fetal and Neonatal Considerations
Transient fetal or neonatal thyroid suppression may occur with methimazole therapy but is usually self-limited and rarely requires treatment. 1, 2
Inform the newborn's physician about maternal hyperthyroidism and methimazole exposure so appropriate neonatal thyroid monitoring can be arranged. 1, 2
Monitor fetal heart rate and growth in women with Graves' disease throughout pregnancy. 1
Risks of Inadequate Treatment
Untreated or inadequately treated maternal hyperthyroidism increases the risk of severe preeclampsia, preterm delivery, heart failure, miscarriage, and low birth weight. 1, 2
These maternal and fetal complications far outweigh the risks of appropriately dosed methimazole therapy after the first trimester. 1, 2
Surgical and Radioactive Iodine Considerations
Radioactive iodine (I-131) is absolutely contraindicated throughout pregnancy because it causes fetal thyroid ablation. 1, 2, 3
Women who have received I-131 must wait at least four months before initiating breastfeeding. 1, 2
Thyroidectomy is reserved only for women who fail to achieve control with thioamides or develop severe drug intolerance (agranulocytosis, marked hepatotoxicity). 1, 2
If surgery is necessary, perform thyroidectomy during the second trimester to minimize fetal risk. 1, 2
Breastfeeding
Both propylthiouracil and methimazole are compatible with breastfeeding, as only minimal drug amounts enter breast milk. 1, 2
Mothers may safely nurse while taking methimazole after delivery. 1, 2
Critical Pitfalls to Avoid
Do not use methimazole during the first trimester—the teratogenic risk, though small, is specific and preventable by using PTU instead. 1, 2, 3
Do not continue PTU beyond the first trimester—this unnecessarily exposes the mother to hepatotoxicity risk when methimazole is safer. 1
Do not target mid-normal or low-normal free T4 levels—this increases the risk of fetal hypothyroidism and goiter. 1, 3
Do not initiate methimazole during active labor if the patient is biochemically controlled—delivery should proceed without delay, and thyroid function can be reassessed postpartum. 1